journal cover

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Aug 28, 2019

Jennifer Keating LittonBanu K. Arun

Get paper from

Abstract

Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer. Eligibilit...read more

Mentioned in this Paper

Anemia
Biopsy
Blood Transfusion
Malignant Neoplasm of Breast
Cations
Hormone Receptor
Neoplasms
Neutropenia
Physicians
Thrombocytopenia
85
2
6
Paper Details
References
  • References15
  • Citations
12
  • References15
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Hormone-Related Cancers

This feed focuses on hormone-related cancers including cancer of the breast, endometrium, ovary, prostate, testis, thyroid, and bone, all of which share unique mechanisms of carcinogenesis. Here is the latest research.

Inflammatory Breast Neoplasms

Inflammatory breast cancer is a rare disease characterized by edema and redness of the breast. This is caused by metastatic breast cancer cells blocking lymphatic vessels. Discover the latest research on Inflammatory breast cancer here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute focuses on advancing cancer tratment through supporting clinical trials and translational research. Follow this feed to stay up to date on research from this institute.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

© 2019 Meta ULC. All rights reserved

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Aug 28, 2019

Jennifer Keating LittonBanu K. Arun

PMID: 31461380

DOI: 10.1200/jco.19.01304

Abstract

Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer. Eligibilit...read more

Mentioned in this Paper

Anemia
Biopsy
Blood Transfusion
Malignant Neoplasm of Breast
Cations
85
2
6

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References15
  • Citations
12
  • References15
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/neoadjuvant-talazoparib-for-patients-with/31461380